7 days ago | By Xconomy
Software startup Deep 6 AI has developed a system that analyzes a range of patient health records to accelerate the process of identifying candidates for clinical trial recruitment-a longstanding bottleneck in the drug development process. The Pasadena, CA-based company, founded in 2015, recently raised $17M in Series A funding to advance its software system, which aims to use artificial intelligence tools to resolve one of research's biggest challenges: enrolling patients to participate in trials. About 80 percent of clinical trials miss enrollment timelines, and nearly one-third of Phase...
Read more ...
Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...
Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...
This conference is designed for experts in academia and industries working in the tissue science and regenerative field, this conference will examine cutting-edge research in... Read more ...
For Mannie Liscum, thinking is a privilege, and his job gives him the chance to be fascinated by human's capacity to conceptualize and learn new things. “It's my goal to use as... Read more ...
When Paul Hudson lays out his R&D vision for Sanofi tomorrow, he will have a new slate of interleukin therapies and a synthetic biology platform to boast about. The French... Read more ...
AveXis Inc.: OverviewReady to join a team committed to developing and commercializing gene therapies for patients and families devastated by rare neurological gene San Diego... Read more ...
Focus will be on one or more areas such as design, implementation and/or start-up of new and/or existing facilities with respect to process and/or clean utility...From... Read more ...
Abstract Pineoblastomas are rare, aggressive pediatric brain tumors of the pineal gland with modest overall survival despite intensive therapy. We sought to define the clinical... Read more ...
Abstract Background Adenosine-to-inosine RNA editing, mediated by ADAR1 and ADAR2, occurs at tens of thousands to millions of sites across mammalian transcriptomes. A-to-I... Read more ...
Abstract In recent years, the innovation of gene-editing tools such as the CRISPR/Cas9 system improves the translational gap of treatments mediated by gene therapy. The... Read more ...
Abstract Zincphyrin IV is a potential organic photosensitizer which is of significant interest for applications in biomedicine, materials science, agriculture , and chemistry... Read more ...
Abstract Polycyclic tetramate macrolactams are a widely distributed class of structurally complex natural products, and most of them exhibit multiple biological activities... Read more ...
Abstract In Drosophila melanogaster , the chromatin of interphase polytene chromosomes appears as alternating decondensed interbands and dense black or thin gray bands... Read more ...